Tumor-Associated Macrophages: Combination of Therapies, the Approach to Improve Cancer Treatment

doi:10.3390/ijms22137239

Review

. 2021 Jul 5;22(13):7239.

doi: 10.3390/ijms22137239.

Tumor-Associated Macrophages: Combination of Therapies, the Approach to Improve Cancer Treatment

Pedram Moeini¹, Paulina Niedźwiedzka-Rystwej²

Affiliations

¹ Plant Virology Research Center, Shiraz University, Shiraz 71441-65186, Iran.
² Institute of Biology, University of Szczecin, 71-412 Szczecin, Poland.

PMID: 34281293
PMCID: PMC8269174
DOI: 10.3390/ijms22137239

Review

Tumor-Associated Macrophages: Combination of Therapies, the Approach to Improve Cancer Treatment

Pedram Moeini et al. Int J Mol Sci. 2021.

. 2021 Jul 5;22(13):7239.

doi: 10.3390/ijms22137239.

Authors

Pedram Moeini¹, Paulina Niedźwiedzka-Rystwej²

Affiliations

¹ Plant Virology Research Center, Shiraz University, Shiraz 71441-65186, Iran.
² Institute of Biology, University of Szczecin, 71-412 Szczecin, Poland.

PMID: 34281293
PMCID: PMC8269174
DOI: 10.3390/ijms22137239

Abstract

Macrophages are one of the most important cells of the innate immune system and are known for their ability to engulf and digest foreign substances, including cellular debris and tumor cells. They can convert into tumor-associated macrophages (TAMs) when mature macrophages are recruited into the tumor microenvironment. Their role in cancer progression, metastasis, and therapy failure is of special note. The aim of this review is to understand how the presence of TAMs are both advantageous and disadvantageous in the immune system.

Keywords: cancer; macrophage; therapeutic target; tumor; tumor-associated macrophage (TAM).

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

**Figure 1**
Macrophage polarization model from an original monocyte into different subtypes.

**Figure 2**
M1- and M2-like macrophage significance in cancer treatment.

See this image and copyright information in PMC

Cited by

The Interface of Tumour-Associated Macrophages with Dying Cancer Cells in Immuno-Oncology.
Vanmeerbeek I, Govaerts J, Laureano RS, Sprooten J, Naulaerts S, Borras DM, Laoui D, Mazzone M, Van Ginderachter JA, Garg AD. Vanmeerbeek I, et al. Cells. 2022 Dec 2;11(23):3890. doi: 10.3390/cells11233890. Cells. 2022. PMID: 36497148 Free PMC article. Review.
Unraveling the enigma of tumor-associated macrophages: challenges, innovations, and the path to therapeutic breakthroughs.
Shao S, Miao H, Ma W. Shao S, et al. Front Immunol. 2023 Nov 14;14:1295684. doi: 10.3389/fimmu.2023.1295684. eCollection 2023. Front Immunol. 2023. PMID: 38035068 Free PMC article. Review.
Single cell RNA sequencing reveals differentiation related genes with drawing implications in predicting prognosis and immunotherapy response in gliomas.
Zhou Z, Wei J, Yang Z, Bao Y, Jiang W, Lu B, Wang W, Li L. Zhou Z, et al. Sci Rep. 2022 Feb 3;12(1):1872. doi: 10.1038/s41598-022-05686-x. Sci Rep. 2022. PMID: 35115572 Free PMC article.
Ferroptosis and Its Multifaceted Role in Cancer: Mechanisms and Therapeutic Approach.
Chen H, Wang C, Liu Z, He X, Tang W, He L, Feng Y, Liu D, Yin Y, Li T. Chen H, et al. Antioxidants (Basel). 2022 Jul 31;11(8):1504. doi: 10.3390/antiox11081504. Antioxidants (Basel). 2022. PMID: 36009223 Free PMC article. Review.
Monocytes educated by cancer-associated fibroblasts secrete exosomal miR-181a to activate AKT signaling in breast cancer cells.
Pakravan K, Mossahebi-Mohammadi M, Ghazimoradi MH, Cho WC, Sadeghizadeh M, Babashah S. Pakravan K, et al. J Transl Med. 2022 Dec 3;20(1):559. doi: 10.1186/s12967-022-03780-2. J Transl Med. 2022. PMID: 36463188 Free PMC article.

See all "Cited by" articles

References

1. Wynn T.A., Chawla A., Pollard J.W. Macrophage biology in development, homeostasis and disease. Nature. 2013;496:445–455. doi: 10.1038/nature12034. - DOI - PMC - PubMed
1. Yona S., Kim K.W., Wolf Y., Mildner A., Varol D., Breker M., Strauss-Ayali D., Viukov S., Guilliams M., Misharin A., et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity. 2013;38:79–91. doi: 10.1016/j.immuni.2012.12.001. - DOI - PMC - PubMed
1. Biswas S.K. Metabolic reprogramming of immune cells in cancer progression. Immunity. 2015;43:435–449. doi: 10.1016/j.immuni.2015.09.001. - DOI - PubMed
1. Mantovani A., Marchesi F., Malesci A., Laghi L., Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat. Rev. Clin. Oncol. 2017;14:399–416. doi: 10.1038/nrclinonc.2016.217. - DOI - PMC - PubMed
1. Gordon S., Plüddemann A. The mononuclear phagocytic system. Generation of diversity. Front. Immunol. 2019;10:1893. doi: 10.3389/fimmu.2019.01893. - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources

[1] Wynn T.A., Chawla A., Pollard J.W. Macrophage biology in development, homeostasis and disease. Nature. 2013;496:445–455. doi: 10.1038/nature12034. - DOI - PMC - PubMed

[2] Wynn T.A., Chawla A., Pollard J.W. Macrophage biology in development, homeostasis and disease. Nature. 2013;496:445–455. doi: 10.1038/nature12034. - DOI - PMC - PubMed

[3] Yona S., Kim K.W., Wolf Y., Mildner A., Varol D., Breker M., Strauss-Ayali D., Viukov S., Guilliams M., Misharin A., et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity. 2013;38:79–91. doi: 10.1016/j.immuni.2012.12.001. - DOI - PMC - PubMed

[4] Yona S., Kim K.W., Wolf Y., Mildner A., Varol D., Breker M., Strauss-Ayali D., Viukov S., Guilliams M., Misharin A., et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity. 2013;38:79–91. doi: 10.1016/j.immuni.2012.12.001. - DOI - PMC - PubMed

[5] Biswas S.K. Metabolic reprogramming of immune cells in cancer progression. Immunity. 2015;43:435–449. doi: 10.1016/j.immuni.2015.09.001. - DOI - PubMed

[6] Biswas S.K. Metabolic reprogramming of immune cells in cancer progression. Immunity. 2015;43:435–449. doi: 10.1016/j.immuni.2015.09.001. - DOI - PubMed

[7] Mantovani A., Marchesi F., Malesci A., Laghi L., Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat. Rev. Clin. Oncol. 2017;14:399–416. doi: 10.1038/nrclinonc.2016.217. - DOI - PMC - PubMed

[8] Mantovani A., Marchesi F., Malesci A., Laghi L., Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat. Rev. Clin. Oncol. 2017;14:399–416. doi: 10.1038/nrclinonc.2016.217. - DOI - PMC - PubMed

[9] Gordon S., Plüddemann A. The mononuclear phagocytic system. Generation of diversity. Front. Immunol. 2019;10:1893. doi: 10.3389/fimmu.2019.01893. - DOI - PMC - PubMed

[10] Gordon S., Plüddemann A. The mononuclear phagocytic system. Generation of diversity. Front. Immunol. 2019;10:1893. doi: 10.3389/fimmu.2019.01893. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Tumor-Associated Macrophages: Combination of Therapies, the Approach to Improve Cancer Treatment

Affiliations

Tumor-Associated Macrophages: Combination of Therapies, the Approach to Improve Cancer Treatment

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Related information

LinkOut - more resources

Full Text Sources